Global /United States /Healthcare /Biotechnology /IMA

ImageneBio, Inc.

IMA

• NASDAQ: IMA • Delayed

5.93USD 3.1%

As of 13 June 2026, ImageneBio, Inc. has a market cap of $66.33M USD, ranking #28490 globally and #4268 in the United States. It ranks #2580 in the Healthcare sector, and #499 in the Biotechnology industry.

Global Rank

28490

Country Rank

4268

Sector Rank

2580

Industry Rank

499

Key Stats

Market Cap

$66.33MUSD

Enterprise Value

-$65.99MUSD

Revenue (TTM)

$800.0KUSD

EBITDA (TTM)

-$48.05MUSD

Net Income (TTM)

-$52.4MUSD

PS Ratio

83.0

PB Ratio

0.5

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Kristin Yarema open_in_new

Employees

Founded

2019

Website

inmagenebio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
3.1%	0.3%	17%	-21%	-33%	-16%	-97%	-99%	-100%

News

IMA Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	IMA ImageneBio Inc ISIN: US45175G2075 Shares Out.: Shares Outstanding: 11.279M¹ Shares Float: 7.486M² TV: TradingView: NASDAQ: IMA SA: Stock Analysis: NASDAQ: IMA YF: Yahoo Finance: IMA GF: Google Finance: NASDAQ: IMA NQ: NASDAQ: IMA BA: Barron's: IMA MS: Morningstar: XNAS: IMA	5.93 USD	TV: TradingView: NASDAQ: IMA SA: Stock Analysis: NASDAQ: IMA YF: Yahoo Finance: IMA GF: Google Finance: NASDAQ: IMA NQ: NASDAQ: IMA BA: Barron's: IMA MS: Morningstar: XNAS: IMA

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About ImageneBio, Inc.

ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 275K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 241K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 42K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 40K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 38K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 27K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 72K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 67K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 64K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 64K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 42K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 39K%	-	Germany

chevron_leftBack